RELPI
4.1.2022 15:02:06 CET | Business Wire | Press release
The Real Estate Limited Partner Institute (RELPI) today announced the expansion of its compelling Interests Aligned programs to Europe and the United Kingdom with the appointment of institutional real estate investment and media professional Arno Van Grondelle as CEO of RELPI Europe.
RELPI’s intimate, focused and curated local meet-ups foster open conversation and deep relationships among leading stakeholders in the investment and allocation of capital in real estate. The series was formally launched in 2021 with events in Austin, New York and Philadelphia, and was met with an overwhelming interest and attendance. In addition to the expansion into Europe and the United Kingdom, RELPI has announced events in Chicago, Cleveland, Los Angeles, San Francisco and New York so far in 2022.
“Our success and expansion reflect the pent-up demand for in-person gatherings and virtual meetings of informed, high-level executives to share insights, ideas and transparent conversations devoted to best practices in institutional real estate asset allocation and investment,” said RELPI’s CEO and Executive Director Jonathan Schein. “In less than six months, the RELPI community has grown to include more than 125 pension funds, endowments foundations and family offices, as well as more than 50 fund managers.”
The addition of Arno Van Grondelle as CEO of RELPI Europe will accelerate this expansion. Mr. Van Grondelle brings extensive knowledge and leadership experience from his many years working in the institutional real estate investment and media industries. Most recently he served as Managing Director of Europe at Institutional Real Estate Inc., responsible for client relations, business development and sales for Institutional Real Estate Europe magazine. He previously served as International Sales Director at PropertyEU, where he was responsible for the sales of PropertyEU's comprehensive media portfolio, including PropertyEU magazine and EXPO Real's Preview and Daily News.
"Arno’s wealth of knowledge, experience and relationships in the European investor and LP arena will solidify RELPI’s fast mover status in the industry,” said Mr. Schein "His professionalism and market acumen will make a great addition to our growing platform designed to connect key players for the mutual benefit of the dynamic private equity real estate investment and capital industries.”
“I am very excited to join RELPI and further build this community in Europe,” said Mr. Van Grondelle. “We are dedicated to bringing together real estate institutional investors, fund managers, operating companies and those organizations allied to the industry on a local, regional and global scale.”
The Interests Aligned series are designed to be streamlined and efficient (just three hours long) with a strong emphasis on social networking, offering RELPI’s unique value proposition – intimate, ultrahigh-value gatherings, in a streamlined, economically effective manner, with “proximity” in mind.
For more information about the Interests Aligned series, to register or inquire about membership, please visit: www.RELPI.org
About RELPI
As an established producer of successful meetings, events and conferences devoted to the global institutional investment community for the commercial real estate class, with “proximity” as the prime value proposition, RELPI is perfectly positioned to deliver a best-of-both-worlds solution: intimate, ultrahigh-value gatherings in a streamlined, economically effective way. From “virtual salons” and global summits focused on investors in all major global markets, to emerging manager programs and even “private label,” bespoke roundtables, RELPI is enabling tomorrow’s business connectivity today.
https://www.relpi.org
View source version on businesswire.com: https://www.businesswire.com/news/home/20220104005129/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom